Hepatocellular Carcinoma

On this page

HCC Basics - Liver's Dark Side

  • Definition: Primary malignancy of the liver arising from hepatocytes.
  • Epidemiology: 6th most common cancer worldwide; 3rd leading cause of cancer death. Significant burden in India due to Hepatitis B (HBV) & C (HCV) prevalence.
  • Risk Factors:
    • Chronic Viral Hepatitis (HBV, HCV)
    • Alcoholic Liver Disease
    • Non-alcoholic Fatty Liver Disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)
    • Aflatoxin B1 exposure (e.g., contaminated groundnuts, corn)
    • Cirrhosis (present in ~80-90% of HCC cases, from any cause)
    • 📌 Mnemonic: 'HH AAN' (HBV, HCV, Alcohol, Aflatoxin, NAFLD)

⭐ Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver, accounting for approximately 75-85% of all primary liver cancers globally.

Diagnosis - Spotting the Enemy

  • Screening (High-Risk: Cirrhosis, Chronic HBV/HCV):
    • Ultrasound (USG) every 6 months.
    • Serum Alpha-fetoprotein (AFP); ↑AFP > 20 ng/mL is abnormal.
  • Diagnostic Imaging (Key):
    • Multiphase CT or MRI (preferred):
      • Hallmark: Arterial Phase Hyperenhancement (APHE) & Portal/Venous Phase Washout.
    • LI-RADS (Liver Imaging Reporting and Data System) used for characterization. LI-RADS table and CT images of HCC
  • Tumor Markers:
    • AFP > 400 ng/mL highly suggestive.
    • Others: AFP-L3, PIVKA-II (DCP).
  • Biopsy:
    • For LI-RADS 3/4 or indeterminate lesions.
    • If imaging non-diagnostic, or in non-cirrhotic liver.
    • Risk: Needle-track seeding.

⭐ In cirrhotic patients, classic imaging features (arterial phase hyperenhancement and portal/venous phase washout) are diagnostic for HCC, often obviating biopsy.

Staging & Prognosis - Sizing Up Trouble

  • Core Principle: Staging dictates therapy & predicts survival.
  • BCLC (Barcelona Clinic Liver Cancer): Gold standard.

    ⭐ The Barcelona Clinic Liver Cancer (BCLC) staging system is preferred as it links stage with treatment strategy and prognosis.

  • BCLC Stages & Treatment:
    • 0 (Very Early) / A (Early): Curative intent (resection, transplant, RFA).
    • B (Intermediate): TACE.
    • C (Advanced): Systemic therapy (e.g., Sorafenib, Lenvatinib).
    • D (Terminal): Best supportive care.
  • Key Prognostic Factors:
    • Tumor burden: Size, number, vascular invasion (MVI).
    • Liver function reserve: Child-Pugh score.
    • Patient's overall health: ECOG performance status.
    • Serum Biomarkers: AFP levels.

Treatment - Battle Plan

  • BCLC 0 & A (Very Early & Early Stage): Curative Intent
    • Surgical Resection: Child-Pugh A, adequate liver reserve.
    • Liver Transplantation: 📌 Milan Criteria: Single tumor ≤5 cm, or up to 3 tumors each ≤3 cm; no macrovascular invasion; no extrahepatic spread.
    • Ablation (RFA/MWA): For tumors <3 cm, non-surgical candidates.
  • BCLC B (Intermediate Stage): Loco-regional Therapies
    • TACE (Transarterial Chemoembolization): Multinodular, preserved liver function.
    • TARE/SIRT (Y-90 Radioembolization): Alternative for TACE-unsuitable/refractory.
  • BCLC C (Advanced Stage): Systemic Therapy
    • Atezolizumab + Bevacizumab (Preferred 1st line).
    • TKIs (Sorafenib, Lenvatinib).
  • BCLC D (Terminal Stage): Best Supportive Care.

HCC Treatment Algorithm based on BCLC Staging

⭐ For advanced HCC (BCLC C), Atezolizumab-Bevacizumab is a preferred first-line systemic therapy, showing improved survival over Sorafenib monotherapy.

High‑Yield Points - ⚡ Biggest Takeaways

  • Chronic Hepatitis B & C and cirrhosis are major risk factors for HCC.
  • Screening in high-risk patients involves serum AFP and ultrasound every 6 months.
  • Diagnosis often relies on characteristic imaging: arterial phase hyperenhancement and venous/delayed phase washout on CT/MRI.
  • Milan criteria (single tumor ≤5 cm, or up to 3 tumors each ≤3 cm) are key for liver transplant eligibility.
  • Surgical resection offers the best chance for cure in non-cirrhotic patients or those with well-compensated cirrhosis and solitary tumors.
  • TACE (Transarterial Chemoembolization) is a primary palliative treatment for unresectable, localized HCC.
  • Sorafenib and Lenvatinib are first-line systemic therapies for advanced HCC with preserved liver function.
Rezzy AI Tutor

Have doubts about this lesson?

Ask Rezzy, our AI tutor, to explain anything you didn't understand

Practice Questions: Hepatocellular Carcinoma

Test your understanding with these related questions

A patient with a history of alcohol dependence syndrome presents with sudden and unintentional weight loss. What is the most likely diagnosis?

1 of 5

Flashcards: Hepatocellular Carcinoma

1/10

The risk of rupture in hepatic adenoma is estimated to be seen in _____% to 50% of the cases

TAP TO REVEAL ANSWER

The risk of rupture in hepatic adenoma is estimated to be seen in _____% to 50% of the cases

30

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start For Free
Hepatocellular Carcinoma - Free Indian Medical PG Review